CIAM
BTAI icon

Caitong International Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Caitong International Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,642
Closed -$2.63K – 2641
2025
Q4 		$2.63K Buy
+1,642
New +$3.39K ﹤0.01% 1294

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Caitong International Asset Management's BTAI Position: Q1 2026 in Review

Caitong International Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 1,642 shares — an estimated $2.63K sold.

Caitong International Asset Management first reported a position in BTAI in Q4 2025 and held it in 1 quarter. The position peaked at $2.63K in Q4 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Caitong International Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 1,642 BioXcel Therapeutics shares in Q1 2026, an estimated $2.63K.
  • Caitong International Asset Management first reported a position in BioXcel Therapeutics in Q4 2025 and held it in 1 quarter.
  • Caitong International Asset Management's BioXcel Therapeutics position peaked at $2.63K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.